Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy of PD-1 Antibody Sintilimab on Early-stage Multiple Primary Lung Cancer With Ground Glass Density: A Prospective Interventional Two-stage Simon Design Phase II Study.

NCT04026841 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Guangzhou Medical University as lead sponsor.

NCT NCT04026841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04026841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy of PD-1 Antibody Sintilimab on Early-stage Multiple Primary Lung Cancer With Ground Glass Density: A Prospective Interventional Two-stage Simon Design Phase II Study.
Lead sponsor
The First Affiliated Hospital of Guangzhou Medical University
Phase
Phase 2
Overall status
Unknown status
Start date
July 30, 2019
Completion date
February 1, 2020
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple primary lung cancers